

# Package ‘metabook’

May 8, 2026

**Title** Data Sets and Code for ‘‘Meta-Analysis with R’’

**Version** 0.2-0

**Date** 2026-03-13

**Depends** R (>= 4.0.0)

**Suggests** meta, netmeta, metasens, netdose

**Author** Guido Schwarzer [cre, aut] (ORCID:  
<<https://orcid.org/0000-0001-6214-9087>>)

**Maintainer** Guido Schwarzer <[guido.schwarzer@uniklinik-freiburg.de](mailto:guido.schwarzer@uniklinik-freiburg.de)>

**URL** <https://github.com/guido-s/metabook/>

**Description** Data sets and code supporting the second edition of ‘‘Meta-Analysis with R’’; first edition: Schwarzer, Carpenter, and R cker (2015) <[DOI:10.1007/978-3-319-21416-0](https://doi.org/10.1007/978-3-319-21416-0)>.

**LazyData** TRUE

**License** GPL (>= 2)

**Encoding** UTF-8

**RoxygenNote** 7.3.3

**NeedsCompilation** no

**Repository** CRAN

**Date/Publication** 2026-03-13 10:30:02 UTC

## Contents

metabook-package . . . . .	2
Baker2009 . . . . .	3
Bassler2004 . . . . .	4
Curtin2002 . . . . .	6
Dogliotti2014 . . . . .	8
Dong2013 . . . . .	9
Feng2019 . . . . .	11
Franchini2012 . . . . .	13

Furukawa2003 . . . . .	15
Greb2008 . . . . .	16
Greenland1992 . . . . .	18
Gurusamy2011 . . . . .	19
Hamza2021 . . . . .	22
Higgins2008 . . . . .	23
Hong2015 . . . . .	25
Jalota2011 . . . . .	27
Linde2015 . . . . .	28
Linde2016 . . . . .	31
Lloyd2010 . . . . .	33
Moore1998 . . . . .	35
Poole2003 . . . . .	36
Quan2000 . . . . .	38
Senn2013 . . . . .	39
Senn2024 . . . . .	41
Spooner2002 . . . . .	42
Steurer2006 . . . . .	44
Stowe2010 . . . . .	45
Su2018 . . . . .	48
Thompson1999 . . . . .	49
Woods2010 . . . . .	51

---

**Index** **53**

---

metabook-package      *metabook: Data Sets and Code for "Meta-Analysis with R"*

---

**Description**

Data sets and code supporting the second edition of "Meta-Analysis with R" by Schwarzer, Carpenter, and Rucker.

**Author(s)**

Guido Schwarzer <guido.schwarzer@uniklinik-freiburg.de>

**References**

- Balduzzi S, Rucker G, Schwarzer G (2019): How to perform a meta-analysis with R: a practical tutorial. *Evidence-Based Mental Health*, **22**, 153–160
- Schwarzer G, Carpenter JR and Rucker G (2015): *Meta-Analysis with R (Use-R!)*. Springer International Publishing, Switzerland

**See Also**

Useful links:

- <https://github.com/guido-s/metabook/>

---

Baker2009                      *Studies on Pharmacologic Treatments for Chronic Obstructive Pulmonary Disease*

---

### Description

Results from 39 trials examining pharmacologic treatments for chronic obstructive pulmonary disease (COPD).

### Usage

Baker2009

### Format

The data frame contains the following columns:

<b>study</b>	character	study label
<b>year</b>	numeric	year of publication
<b>id</b>	numeric	study ID
<b>treatment</b>	character	treatment
<b>exac</b>	numeric	number of individuals with one or more COPD exacerbations
<b>total</b>	numeric	number of individuals

### Details

This data set comes from a systematic review of randomized controlled trials on pharmacologic treatments for chronic obstructive pulmonary disease (COPD) (Baker et al., 2009).

The primary outcome, occurrence of one or more episodes of COPD exacerbation, is binary (yes / no). For this outcome, five drug treatments (fluticasone, budesonide, salmeterol, formoterol, tiotropium) and two combinations (fluticasone + salmeterol, budesonide + formoterol) were compared to placebo. The authors considered the two combinations as separate treatments instead of evaluating the individual components.

### Concepts

medicine, pulmonology, odds ratios, network meta-analysis, component network meta-analysis

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

### Source

Baker WL, Baker EL, Coleman CI (2009): Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparison meta-analysis. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, **29**(8), 891–905. doi:10.1592/phco.29.8.891

**Examples**

```

if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' has to be used for odds ratio as summary
# measure; by default the risk ratio is used in the metabin function
# called internally.
pw <- pairwise(treatment, exac, total, studlab = paste(study, year),
  data = Baker2009, sm = "OR")

# Conduct random effects network meta-analysis (NMA)
# with placebo as reference
nma <- netmeta(pw, common = FALSE, ref = "plac")

# Show network graph
netgraph(nma, seq = "optimal", start = "prcomp",
  labels = gsub("+", " +\n", trts, fixed = TRUE),
  plastic = TRUE, thickness = "se.common", number = TRUE,
  points = TRUE, cex.points = 5, col.points = "red",
  offset = 0.025)

# Print and plot results for network meta-analysis
nma
forest(nma)

# Conduct component network meta-analysis (CNMA)
cnma <- netcomb(nma)
cnma

# Compare results of NMA and additive CNMA
nb <- netbind(nma, cnma, name = c("Standard NMA", "Additive CNMA"))
forest(nb)

# Use previous settings
settings.meta(oldset)
}

```

---

Bassler2004

---

*Studies on Ketotifen Alone or as Additional Medication for Long-Term Control of Asthma and Wheeze in Children*


---

**Description**

Results from ten trials reporting the physicians' judgement on the overall efficacy of ketotifen for long-term control of asthma and wheeze in children.

**Usage**

Bassler2004

**Format**

The data frame contains the following columns:

<b>study</b>	character	study label
<b>Ee</b>	integer	number of children with treatment success (ketotifen group)
<b>Ne</b>	integer	number of children (ketotifen group)
<b>Ec</b>	integer	number of children with treatment success (control group)
<b>Nc</b>	integer	number of children (control group)
<b>blind</b>	character	blinding of clinicians

**Details**

Results from ten trials reporting the physicians' judgement on the overall efficacy of Ketotifen for long-term control of asthma and wheeze in children. A prespecified subgroup analysis was conducted to evaluate whether the treatment effect is different in trials with adequate blinding compared to trials with inadequate / unclear blinding.

This data set is used as an example in Schwarzer et al. (2015).

**Concepts**

risk ratios, medicine, subgroup analysis

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Bassler D, Mitra AAD, Ducharme FM, Forster J, Schwarzer G (2004): Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. *Cochrane Database of Systematic Reviews*, **1**, CD001384. doi:10.1002/14651858.CD001384.pub2

**References**

Schwarzer G, Carpenter JR and Rücker G (2015): *Meta-Analysis with R (Use-R!)*. Springer International Publishing, Switzerland

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Use DerSimonian-Laird estimator (which was the default in meta in the year 2015).
# Furthermore, print meta-analysis results with two digits.
```

```

oldset <- settings.meta(method.tau = "DL", digits = 2)

# Calculate experimental and control event rates
with(Bassler2004, summary(Ee / Ne))
with(Bassler2004, summary(Ec / Nc))

# Conduct meta-analysis using the inverse variance method
mb3 <- metabin(Ee, Ne, Ec, Nc, method = "I",
  data = Bassler2004, studlab = study)
mb3

# Conduct subgroup analysis comparing trials with adequate blinding
# to trials with inadequate or unclear blinding
mb3s <- update(mb3, subgroup = blind, print.subgroup.name = FALSE)
mb3s

# Conduct subgroup analysis assuming common between-study variance in subgroups
mb3s.c <- update(mb3s, tau.common = TRUE)
mb3s.c

# Use previous settings
settings.meta(oldset)
}

```

---

Curtin2002

---

*Studies on Potassium Supplementation to Reduce Diastolic Blood Pressure*


---

### Description

Results from 21 cross-over studies evaluating the effect of potassium supplementation to reduce diastolic blood pressure.

### Usage

Curtin2002

### Format

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	character	year of publication
<b>N</b>	integer	total sample size
<b>mean</b>	numeric	mean difference in diastolic blood pressure
<b>SE</b>	numeric	standard error
<b>corr</b>	numeric	within-patient correlation

## Details

Results from 21 cross-over studies evaluating the effect of potassium supplementation to reduce diastolic blood pressure (Curtin et al., 2002, Table II).

This data set is used as an example in Schwarzer et al. (2015), Chapter 2.

## Concepts

mean differences

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Curtin F, Altman DG, Elbourne D (2002): Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. *Statistics in Medicine*, **21**(15), 2131–2144. doi:10.1002/sim.1205

## References

Schwarzer G, Carpenter JR and Rucker G (2015): *Meta-Analysis with R (Use-R!)*. Springer International Publishing, Switzerland

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Use DerSimonian-Laird estimator (which was the default in meta in the year 2015).
# Furthermore, print meta-analysis results with two digits.
oldset <- settings.meta(method.tau = "DL", digits = 2)

# Conduct meta-analysis
mg2 <- metagen(mean, SE, studlab = paste(author, year),
  data = Curtin2002, sm = "MD")
mg2

# Use previous settings
settings.meta(oldset)
}
```

Dogliotti2014

*Studies on Antithrombotic Treatments to Prevent Strokes***Description**

Results from 20 trials examining the effectiveness of antithrombotic treatments to prevent strokes in patients with non-valvular atrial fibrillation.

**Usage**

Dogliotti2014

**Format**

The data frame contains the following columns:

<b>study</b>	character	study label
<b>id</b>	numeric	study ID
<b>treatment</b>	character	treatment
<b>stroke</b>	numeric	number of strokes
<b>total</b>	numeric	number of individuals

**Details**

This data set comes from a systematic review aiming to estimate the effects of eight antithrombotic treatments including placebo in reducing the incidence of major thrombotic events in patients with non-valvular atrial fibrillation (Dogliotti et al., 2014).

The review included 20 studies with 79,808 participants, four studies are three-arm studies. The primary outcome is stroke reduction (yes / no).

**Concepts**

medicine, odds ratios, network meta-analysis, Mantel-Haenszel method

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Dogliotti A, Paolasso E, Giugliano RP (2014): Current and new oral antithrombotics in non-valvular atrial fibrillation: A network meta-analysis of 79808 patients. *Heart*, **100**(5), 396–405. doi:10.1136/heartjnl2013304347

**Examples**

```

if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Change appearance of confidence intervals
cilayout("(", "-")

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' has to be used for odds ratio as summary
# measure; by default the risk ratio is used in the metabin function
# called internally.
pw <- pairwise(treat = treatment, n = total, event = stroke,
  studlab = study, data = Dogliotti2014, sm = "OR")

# Print log odds ratios (TE) and standard errors (seTE)
head(pw, 5)[, 1:5]

# Conduct network meta-analysis (NMA) with placebo as reference
nma <- netmeta(pw, ref = "plac")

# Details on excluded study
selvars <- c("studlab", "event1", "n1", "event2", "n2")
subset(pw, studlab == "WASPO, 2007")[, selvars]

# Show network graph
netgraph(nma, seq = "optimal", number = TRUE)

# Conduct Mantel-Haenszel NMA
nma_mh <- netmetabin(pw, ref = "plac")

# Compare results of inverse variance and Mantel-Haenszel NMA
nb <- netbind(nma, nma_mh, random = FALSE,
  name = c("Inverse variance", "Mantel-Haenszel"))
forest(nb, xlim = c(0.15, 2), at = c(0.2, 0.5, 1, 2))

# Print and plot results for inverse variance NMA
nma
forest(nma)

# Use previous settings
settings.meta(oldset)
}

```

**Description**

Results from 41 trials examining the safety of inhaled medications in patients with chronic obstructive pulmonary disease.

**Usage**

Dong2013

**Format**

The data frame contains the following columns:

<b>id</b>	integer	study ID
<b>treatment</b>	character	treatment
<b>death</b>	integer	mortality
<b>randomized</b>	integer	number of individuals

**Details**

This network meta-analysis compared the safety of inhaled medications in patients with chronic obstructive pulmonary disease (Dong et al., 2013).

Mortality was reported in 41 randomized trials, with a total of 52 462 patients. Mortality was low, with 2 408 deaths (4.6%) reported across all studies. There were nine studies that reported zero events in at least one of the treatment arms and three additional studies had zero events in all treatment arms.

This data set was used in Efthimiou et al. (2019) to illustrate the Mantel-Haenszel method for network meta-analysis.

**Concepts**

medicine, odds ratios, network meta-analysis, Mantel-Haenszel method

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Dong, Y.-H., Lin, H.-H., Shau, W.-Y., Wu, Y.-C., Chang, C.-H., & Lai, M.-S. (2013). Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. *Thorax*, **68**(1), 48–56. doi:10.1136/thoraxjnl2012201926

**References**

Efthimiou, O., Rücker, G., Schwarzer, G., Higgins, J., Egger, M., & Salanti, G. (2019). A Mantel-Haenszel model for network meta-analysis of rare events. *Statistics in Medicine*, **38**(16), 2992–3012. doi:10.1002/sim.8158

**Examples**

```

if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Change appearance of confidence intervals
cilayout("(", "-")

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' has to be used for odds ratio as summary
# measure; by default the risk ratio is used in the metabin function
# called internally.
pw <- pairwise(treatment, death, randomized, studlab = id,
  data = Dong2013, sm = "OR")

# Calculated log odds ratios (TE) and standard errors (seTE)
pw[1:3, 1:9]

# Conduct Mantel-Haenszel network meta-analysis (NMA)
nma <- netmetabin(pw, ref = "plac")

# Network graph
netgraph(nma, seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

# Show results for Mantel-Haenszel NMA
nma
forest(nma)

# League table with network estimates in lower triangle and direct
# estimates in upper triangle
netleague(nma)

# Assess inconsistency
print(netsplit(nma), show = "both", ci = TRUE, overall = FALSE,
  nchar.trts = 6)

# Use previous settings
settings.meta(oldset)
}

```

**Description**

Results from 19 studies assessing the prevalence of depression after myocardial infarction

**Usage**

Feng2019

**Format**

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>region</b>	character	country
<b>design</b>	character	study design
<b>source</b>	character	sample source
<b>age</b>	numeric	mean age
<b>males</b>	numeric	percentage of males
<b>first</b>	numeric	percentage of first-time MI
<b>questionnaire</b>	character	self-report questionnaire
<b>interview</b>	character	structured interview
<b>timing</b>	character	timing of depression assessment
<b>depr</b>	integer	subjects with depression
<b>n</b>	integer	sample size

**Details**

This data set comes from a meta-analysis with 19 studies to estimate the prevalence of depression after a myocardial infarction. The variables `depr` and `n` contain the number of depressive patients and the total number of patients.

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Feng L, Li L, Liu W, et al. (2019): Prevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis. *Medicine*, **98**.

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
  # Load meta package
  library("meta")

  # Conduct random effects meta-analysis
  mp1 <- metaprop(depr, n, data = Feng2019,
    studlab = paste(author, year),
```

```

common = FALSE, prediction = TRUE)

# Create forest plot
forest(mp1, digits = 3, xlim = c(0, 1),
       print.pval.Q = FALSE, details = TRUE)
}

```

---

Franchini2012	<i>Studies on Dopamine Agonists to Reduce “Off-Time” in Patients with Advanced Parkinson Disease</i>
---------------	--

---

### Description

Results from 7 trials examining the effectiveness of four dopamine agonists and placebo to reduce “off-time” in patients with advanced Parkinson disease.

### Usage

```
Franchini2012
```

### Format

The data frame contains the following columns:

<b>Study</b>	character	study label
<b>Treatment1</b>	character	treatment 1
<b>y1</b>	numeric	treatment effect arm 1
<b>sd1</b>	numeric	standard deviation arm 2
<b>n1</b>	integer	sample size arm 1
<b>Treatment2</b>	character	treatment 2
<b>y2</b>	numeric	treatment effect arm 2
<b>sd2</b>	numeric	standard deviation arm 2
<b>n2</b>	integer	sample size arm 1
<b>Treatment3</b>	character	treatment 3
<b>y3</b>	numeric	treatment effect arm 3
<b>sd3</b>	numeric	standard deviation arm 2
<b>n3</b>	integer	sample size arm 1

### Details

This network meta-analysis compared the effectiveness of four active treatments and placebo in patients with advanced Parkinson disease (Franchini et al., 2012). The outcome is mean lost work-time reduction in patients given dopamine agonists as adjunct therapy. The data are given as sample size, mean, and standard deviation in each trial arm.

This data set was used as an example in the supplemental material of Dias et al. (2013) where placebo is coded as 1 and the four active drugs as 2 to 5.

**Concepts**

medicine, mean differences, network meta-analysis

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Dias S, Sutton AJ, Ades AE, Welton NJ (2013): Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Medical Decision Making*, **33**(5), 607–617. doi:[10.1177/0272989X12458724](https://doi.org/10.1177/0272989X12458724)

Franchini AJ, Dias S, Ades AE, Jansen JP, Welton, NJ (2012): Accounting for correlation in network meta-analysis with multi-arm trials. *Research Synthesis Methods*, **3**(2), 142–160. doi:[10.1002/jrsm.1049](https://doi.org/10.1002/jrsm.1049)

**Examples**

```
if (requireNamespace("netmeta", quietly = TRUE)) {
  # Load netmeta package
  library("netmeta")

  # Print mean differences with two digits
  oldset <- settings.meta(digits = 2)

  # Transform data from wide arm-based format to contrast-based
  # format. Argument 'sm' must not be provided as the mean difference
  # is the default in R function metacont() called internally.
  pw <- pairwise(list(Treatment1, Treatment2, Treatment3),
    n = list(n1, n2, n3),
    mean = list(y1, y2, y3),
    sd = list(sd1, sd2, sd3),
    data = Franchini2012, studlab = Study, sm = "MD")

  # Show calculated mean differences (TE) for first three studies
  pw[1:5, c(3:7, 10, 1)]

  # Conduct network meta-analysis
  nma <- netmeta(pw)
  nma

  # Draw network graph
  netgraph(nma, points = TRUE, cex.points = 3, cex = 1.5,
    plastic = TRUE, thickness = "se.fixed",
    iterate = TRUE, start = "eigen")

  # Use previous settings
  settings.meta(oldset)
}
```

---

Furukawa2003      *Studies on Low Dosage Tricyclic Antidepressants for the Treatment of Depression*

---

### Description

Results on depression severity from 17 studies comparing low dosage tricyclic antidepressants (TCA) and placebo for the treatment of depression.

### Usage

Furukawa2003

### Format

The data frame contains the following columns:

<b>author</b>	character	First author with information on dosage in parentheses
<b>Ne</b>	integer	number of patients in low TCA group
<b>Me</b>	numeric	depression severity (low TCA)
<b>Se</b>	numeric	standard deviation (low TCA)
<b>Nc</b>	integer	number of patients in placebo group
<b>Mc</b>	numeric	depression severity (placebo)
<b>Sc</b>	numeric	standard deviation (placebo)
<b>measure</b>	character	depression scale

### Details

Furukawa et al. (2003) carried out a systematic review comparing low dosage tricyclic antidepressants (TCA) with placebo for the treatment of depression. They reported the effect on presence/absence of depression and on depression severity at various time points. Here we focus on depression severity at four weeks. Most studies used some version of the Hamilton Depression Rating Scale, however, some studies used the Montgomery-Asberg Depression Rating Scale. Accordingly, it is not possible to pool the estimated effects directly.

This data set is used as an example in Schwarzer et al. (2015).

### Concepts

standardized mean differences

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Furukawa TA, McGuire H, Barbui C (2003): Low dosage tricyclic antidepressants for depression. *Cochrane Database of Systematic Reviews*, **3**, CD003197. doi:10.1002/14651858.CD003197

**References**

Schwarzer G, Carpenter JR and Rücker G (2015): *Meta-Analysis with R (Use-R!)*. Springer International Publishing, Switzerland

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Use RevMan5 settings
oldset <- settings.meta("RevMan5", digits = 2)

# Conduct random effects meta-analysis with Hedges' g as effect measure
mc2 <- metacont(Ne, Me, Se, Nc, Mc, Sc, common = FALSE,
  data = Furukawa2003, sm = "SMD")
mc2

# Use previous settings
settings.meta(oldset)
}
```

---

Greb2008

*Trials on High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma*

---

**Description**

Results on complete response from 14 trials evaluating high-dose chemotherapy with autologous stem cell transplantation in patients with aggressive non-Hodgkin lymphoma.

**Usage**

Greb2008

**Format**

The data frame contains the following columns:

<b>study</b>	character	study label
<b>Ee</b>	integer	complete responses (high-dose chemotherapy)
<b>Ne</b>	integer	number of patients (high-dose chemotherapy)

<b>Ec</b>	integer	complete responses (standard chemotherapy)
<b>Nc</b>	integer	number of patients (standard chemotherapy)

## Details

Greb et al. (2008) conducted a Cochrane Review to assess the effects of high-dose chemotherapy with autologous stem cell transplantation as part of the first-line treatment of adult patients with aggressive non-Hodgkin lymphoma. The primary outcome was survival time; the binary outcome 'complete response' was one of several secondary outcomes. For binary outcomes, the Cochrane review used the risk ratio and the common effect model.

This data set is used as an example in Schwarzer et al. (2015).

## Concepts

medicine, oncology, risk ratios

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Greb A, Bohlius J, Schiefer D, et al. (2008): High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. *Cochrane Database of Systematic Reviews*, **1**, doi:10.1002/14651858.CD004024.pub2

## References

Schwarzer G, Carpenter JR and Rucker G (2015): *Meta-Analysis with R (Use-R!)*. Springer International Publishing, Switzerland

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Use RevMan 5 settings
oldset <- settings.meta("RevMan5")

# Conduct common effect meta-analysis with risk ratio as effect measure
mb1 <- metabin(Ee, Ne, Ec, Nc,
  data = Greb2008, studlab = study,
  label.e = "High dose", label.c = "Standard",
  label.left = "Favours standard chemotherapy",
  label.right = "Favours high dose chemotherapy",
  col.label.left = "red", col.label.right = "green")
mb1

# Create forest plot
```

```

forest(mb1)

# Use previous settings
settings.meta(oldset)
}

```

---

Greenland1992	<i>Case-Control Studies on Impact of Alcohol Consumption on Breast Cancer Risk</i>
---------------	--

---

### Description

Results from 16 case-control studies evaluating the impact of alcohol consumption on breast cancer risk.

### Usage

Greenland1992

### Format

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>b</b>	numeric	adjusted log risk ratio
<b>SE</b>	numeric	standard error

### Details

Greenland and Longecker (1992) describe a method to combine trend estimates from summarised dose-response data. A meta-analysis of 16 case-control studies evaluating the impact of alcohol consumption on breast cancer risk was used as an illustrative example. The estimates are the increase in the log relative risk of breast cancer associated with an average daily alcohol consumption of 1g.

The data are provided in Greenland and Longecker (1992), Table 3.

### Concepts

epidemiology, risk ratios

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Greenland S, Longnecker MP (1992): Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *American Journal of Epidemiology*, **135**(11): 1301–9.

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Inverse variance method
mg <- metagen(b, SE, data = Greenland1992,
  studlab = paste(author, year), sm = "RR",
  random = FALSE, overall.hetstat = FALSE,
  backtransf = FALSE)
# Overall result
print(mg, digits = 5)
# Standard error for common effect estimate
round(mg$seTE.common, 5)
}
```

---

Gurusamy2011

*Studies on Interventions to Reduce Mortality after Liver Transplantation*

---

**Description**

Results from 14 trials examining the mortality risk of interventions for decreasing blood loss and blood transfusion requirements during liver transplantation.

**Usage**

Gurusamy2011

**Format**

The data frame contains the following columns:

<b>study</b>	character	study information
<b>treatment</b>	character	treatment
<b>death</b>	integer	mortality at 60 days post-transplantation
<b>n</b>	integer	number of individuals

## Details

This network meta-analysis compared the effectiveness of seven interventions for decreasing blood loss and blood transfusion requirements during liver transplantation (Gurusamy et al., 2011).

Fourteen studies reported mortality at 60 days, in 1,002 patients. Forty-five deaths were reported across all studies (4.5%). Six studies observed deaths in all treatment arms while three studies did not observe any deaths.

This data set was used in Efthimiou et al. (2019) to introduce the Mantel-Haenszel method for network meta-analysis.

One of the treatments (solvent detergent plasma) was only included in one study with zero events in both treatment arms; this study was excluded from all network meta-analyses. In addition, no death was observed in the antithrombin III arm of the only study evaluating this treatment which was excluded from the Mantel-Haenszel network meta-analysis.

## Concepts

medicine, odds ratios, network meta-analysis, Mantel-Haenszel methods

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR (2011): Methods to decrease blood loss and transfusion requirements for liver transplantation. *Cochrane Database of Systematic Reviews*, **12**, CD009052. doi:[10.1002/14651858.CD009052.pub2](https://doi.org/10.1002/14651858.CD009052.pub2)

## References

Efthimiou O, Rucker G, Schwarzer G, Higgins J, Egger M, Salanti G (2019): A Mantel-Haenszel model for network meta-analysis of rare events. *Statistics in Medicine*, **38**(16), 2992–3012. doi:[10.1002/sim.8158](https://doi.org/10.1002/sim.8158)

## Examples

```
# Only study evaluating solvent detergent plasma
subset(Gurusamy2011, study == "Williamson 1999")

# Only study evaluating antithrombin III
subset(Gurusamy2011, study == "Baudo 1992")

if (requireNamespace("netmeta", quietly = TRUE)) {
  # Load netmeta package
  library("netmeta")

  # Print odds ratios and confidence limits with two digits
  oldset <- settings.meta(digits = 2)
```

```
# Change appearance of confidence intervals
cilayout("(", "-")

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' has to be used for odds ratio as summary
# measure; by default the risk ratio is used in the metabin function
# called internally.
pw <- pairwise(treatment, death, n, studlab = study,
  data = Gurusamy2011, sm = "OR")

# Conduct Mantel-Haenszel network meta-analysis (NMA)
nma_MH <- netmetabin(pw, ref = "cont")

# Conduct inverse variance (IV) network meta-analysis
nma_IV <- netmeta(pw, ref = "cont")

# Network graph (Mantel-Haenszel NMA)
netgraph(nma_MH, seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

# Full network graph (based on inverse variance method, including
# study comparing Antithrombin III with Control/Placebo)
netgraph(nma_IV,
  seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

# Compare results for Mantel-Haenszel and IV NMA
forest(netbind(nma_MH, nma_IV,
  random = FALSE, name = c("MH NMA", "IV NMA")))

# Show results for Mantel-Haenszel NMA
nma_MH
forest(nma_MH)

# League table with network estimates in lower triangle and direct
# estimates in upper triangle
netleague(nma_MH)

# Assess inconsistency
print(netsplit(nma_MH), show = "both", ci = TRUE, overall = FALSE,
  nchar.trts = 6)

# Use previous settings
settings.meta(oldset)
}
```

Hamza2021

*Antidepressants Dataset for Dose-Response Network Meta-Analysis***Description**

Results from 170 trials examining 20 antidepressants and placebo in adults with major depressive disorder.

**Usage**

Hamza2021

**Format**

The data frame contains the following columns:

<b>id</b>	numeric	study ID
<b>drug</b>	character	treatment
<b>dose</b>	numeric	drug dose
<b>resp</b>	numeric	number of responders in treatment arm
<b>total</b>	numeric	sample size in treatment arm
<b>rob</b>	character	risk of bias (low / high)
<b>age</b>	numeric	mean age in treatment arm
<b>year</b>	numeric	year of publication
<b>year.c</b>	numeric	year centered around 2010
<b>class</b>	character	drug class
<b>dose_label</b>	ordered	drug dose as licensed or lower / higher
<b>dose_flux</b>	numeric	fluoxetine-equivalent dose
<b>varlnOR</b>	character	variance of log odds ratio (comparison to reference)

**Details**

This dataset goes back to the network meta-analysis by Cipriani et al. (2018) evaluating 20 antidepressants and placebo in adults with major depressive disorder. The primary outcome is the response rate, defined as the proportion of patients achieving at least a 50% reduction in symptoms.

The dataset and code to conduct a Bayesian dose-response network meta-analysis is publicly available on Zenodo (Hamza et al., 2021). The data have been used in two methodological publications on statistical methods for dose-response network meta-analysis (Hamza et al., 2024; Petropoulou et al., 2025). A reduced version of this data set is available in R package **netdose** under the name 'antidepressants'.

The data set is in long arm-based format, i.e., one treatment arm per row.

**Concepts**

medicine, depression, odds ratios, component network meta-analysis

**Source**

Hamza T, Furukawa TA, Orsini N, Cipriani A, Iglesias C, Salanti G (2021): A dose-effect network meta-analysis model: an application in antidepressants. *Zenodo*. doi:10.5281/zenodo.5866456

**References**

Cipriani A et al. (2018): Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*, **391**, 1357–66

Hamza T, Furukawa TA, Orsini N, Cipriani A, Iglesias CP, Salanti G (2024): A dose-effect network meta-analysis model with application in antidepressants using restricted cubic splines. *Statistical Methods in Medical Research*, **33**, 1461–72

Petropoulou M, Rucker G, Schwarzer G (2026): Network meta-analysis with dose-response relationships. *BMC Medical Research Methodology*, **26**, 17

**Examples**

```
if (requireNamespace("netdose", quietly = TRUE)) {
# Load netdose package
library("netdose")

pw <- pairwise(agent = drug, dose = dose, studlab = id,
  event = resp, n = total, data = Hamza2021, sm = "OR")

## Not run:
# Do not execute without user input due to the long run time
drnma.quad <- netdose(TE, seTE, agent1, dose1, agent2, dose2, studlab,
  data = pw, method = "quadratic")
dotplot(drnma.quad)
plot(drnma.quad)

## End(Not run)
}
```

---

Higgins2008

*Trials on Haloperidol in Schizophrenia*


---

**Description**

Results on clinical improvement after therapy from 17 trials evaluating haloperidol in patients with schizophrenia.

**Usage**

Higgins2008

## Format

The data frame contains the following columns:

<b>author</b>	character	study label
<b>resp.halo</b>	integer	number of responders (haloperidol group)
<b>fail.halo</b>	integer	number of failures (haloperidol group)
<b>miss.halo</b>	integer	number of missing observations (haloperidol group)
<b>resp.plac</b>	integer	number of responders (placebo group)
<b>fail.plac</b>	integer	number of failures (placebo group)
<b>miss.plac</b>	integer	number of missing observations (placebo group)

## Details

Higgins et al. (2008) suggested several imputation methods for the meta-analysis of binary outcomes with missing data. The example data set with 17 trials comes originally from a Cochrane review comparing haloperidol with placebo for the treatment of schizophrenia. While the antipsychotic benefits of haloperidol were identified in the 1950's, trials in this patient population are prone to high proportions of missing outcome data, often due to insufficient compliance with randomised controlled trial protocols.

The outcome is clinical improvement after therapy. For each study, the number of responders, failures, and missing observations are available.

## Concepts

psychiatry, odds ratios, missing data

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Higgins JPT, White IR, Wood AM (2008): Imputation methods for missing outcome data in meta-analysis of clinical trials. *Clinical Trials*, **5**: 225-39

## Examples

```
if (requireNamespace("metasens", quietly = TRUE)) {
  # Load metasens package
  library("metasens")

  # Print odds ratios and confidence limits with three digits
  oldset <- settings.meta(digits = 3)

  # Conduct common effect meta-analysis of available data
  ma <- metabin(resp.halo, resp.halo + fail.halo,
    resp.plac, resp.plac + fail.plac,
    data = Higgins2008, studlab = author,
    sm = "OR", method = "Inverse", random = FALSE,
```

```

label.e = "Haloperidol", label.c = "Placebo",
label.left = "Favours placebo",
label.right = "Favours haloperidol")

# Best case scenario for haloperidol
ma_b <- metamiss(ma, miss.halo, miss.plac,
  method.miss = "b", small.values = "undesirable")
# Worst case scenario for haloperidol
ma_w <- metamiss(ma, miss.halo, miss.plac,
  method.miss = "w", small.values = "undesirable")

# Forest plot
ma_sens <- metamerger(ma, ma_b, text.pooled2 = "Best case scenario")
ma_sens <- metamerger(ma_sens, ma_w, text.pooled2 = "Worst case scenario")
forest(ma_sens)
}

```

---

Hong2015

*Studies on Interventions for Patients with Knee Pain Secondary to Osteoarthritis*


---

### Description

Results from 54 trials comparing physical therapy interventions for community-dwelling adults with knee pain secondary to osteoarthritis.

### Usage

Hong2015

### Format

The data frame contains the following columns:

<b>id</b>	numeric	study ID
<b>trt</b>	character	intervention
<b>n</b>	numeric	number of individuals
<b>mean_pain</b>	numeric	mean (pain outcome)
<b>sd_pain</b>	numeric	standard deviation (pain outcome)
<b>mean_disability</b>	numeric	mean (disability outcome)
<b>sd_disability</b>	numeric	standard deviation (disability outcome)

### Details

This data set comprises 54 trials from a network meta-analysis comparing 11 physical therapy interventions, including 'placebo' and 'no treatment' for community-dwelling adults with knee pain secondary to osteoarthritis (Hong et al., 2015).

Two patient-reported continuous outcomes were considered. Pain was reported in 51 studies, whereas disability was only reported in 26 trials. Evidence was available for all 11 interventions for both outcomes of interest.

### Concepts

medicine, pain, mean differences, network meta-analysis

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

### Source

Hong H, Chu H, Zhang J, Carlin BP (2016): A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. *Research Synthesis Methods*, 7, 6–22. [doi:10.1002/jrsm.1153](https://doi.org/10.1002/jrsm.1153)

### Examples

```
if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Transform data from long arm-based format to contrast-based format
pw_pain <- pairwise(trt, n = n, mean = mean_pain, sd = sd_pain,
  studlab = id, data = Hong2015)
#
pw_dis <- pairwise(trt, n = n, mean = mean_disability, sd = sd_disability,
  studlab = id, data = Hong2015)

# Conduct random effects network meta-analysis (NMA) with
# - 'no treatment' as reference
# - results from split-mouth designs as correlated outcomes
nma_pain <- netmeta(pw_pain, common = FALSE, reference.group = "No treatment",
  small.values = "desirable")
nma_dis <- netmeta(pw_dis, common = FALSE, reference.group = "No treatment",
  small.values = "desirable")

# P-scores
netrank(nma_pain)
netrank(nma_dis)
}
```

---

 Jalota2011

*Studies on Interventions for Pain Prevention of Propofol Injection*


---

### Description

Results from 102 trials comparing seven drug and non-drug interventions to prevent pain during propofol injection.

### Usage

Jalota2011

### Format

The data frame contains the following columns:

<b>id</b>	numeric	study ID
<b>study</b>	character	study label
<b>trt</b>	character	treatment
<b>pain</b>	numeric	number of individuals with pain
<b>n</b>	numeric	number of individuals
<b>author</b>	character	first author
<b>year</b>	numeric	year of publication

### Details

This data set comes from a systematic review of randomized controlled trials on seven drug and non-drug interventions to prevent pain during propofol injection (Jalota et al., 2011). The binary outcome was pain, with relative risk (RR) as a measure of effect.

The core data were extracted from R package **nmadb** using the command `readByID("482001")`.

### Concepts

medicine, pain, risk ratios, network meta-analysis

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

### Source

Jalota L, Kalira V, George E, et al. (2011): Prevention of pain on injection of propofol: systematic review and meta-analysis. *British Medical Journal*, **342**, d1110. doi:10.1136/bmj.d1110.

**Examples**

```

if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print risk ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' is optional as the risk ratio is used by default in
# the metabin function called internally.
pw <- pairwise(trt, pain, n, studlab = study,
  data = Jalota2011, sm = "RR")

# Conduct random effects network meta-analysis (NMA)
# with hand vein as reference
nma <- netmeta(pw, common = FALSE, ref = "Hand vein")

# Show network graph
netgraph(nma, seq = "o", multiarm = TRUE, rotate = 3 / n * 360)

# Print and plot results for network meta-analysis
nma
forest(nma,
  label.left = "Favours other", label.right = "Favours Hand vein")

# Use previous settings
settings.meta(oldset)
}

```

---

Linde2015

---

*Studies on Classes of Antidepressants for the Primary Care Setting*


---

**Description**

Results from 66 trials examining eight classes of antidepressants and placebo for the primary care setting.

**Usage**

Linde2015

**Format**

The data frame contains the following columns:

<b>id</b>	integer	study ID
<b>author</b>	character	first author

<b>year</b>	integer	year of publication
<b>treatment1</b>	character	treatment 1
<b>treatment2</b>	character	treatment 2
<b>treatment3</b>	character	treatment 3
<b>n1</b>	integer	number of patients (arm 1)
<b>resp1</b>	integer	number of early responder (arm 1)
<b>remi1</b>	integer	number of early remissions (arm 1)
<b>loss1</b>	integer	number of patients loss to follow-up (arm 1)
<b>loss.ae1</b>	integer	number of patients loss to follow-up due to adverse events (arm 1)
<b>ae1</b>	integer	number of patients with adverse events (arm 1)
<b>n2</b>	integer	number of patients (arm 2)
<b>resp2</b>	integer	number of early responder (arm 2)
<b>remi2</b>	integer	number of early remissions (arm 2)
<b>loss2</b>	integer	number of patients loss to follow-up (arm 2)
<b>loss.ae2</b>	integer	number of patients loss to follow-up due to adverse events (arm 2)
<b>ae2</b>	integer	number of patients with adverse events (arm 2)
<b>n3</b>	integer	number of patients (arm 3)
<b>resp3</b>	integer	number of early responder (arm 3)
<b>remi3</b>	integer	number of early remissions (arm 3)
<b>loss3</b>	integer	number of patients loss to follow-up (arm 3)
<b>loss.ae3</b>	integer	number of patients loss to follow-up due to adverse events (arm 3)
<b>ae3</b>	integer	number of patients with adverse events (arm 3)

## Details

This data set comes from a systematic review of 8 pharmacological treatments of depression and placebo in primary care with 66 studies (8 of which were 3-arm studies) including 14,785 patients.

The primary outcome is early response, defined as at least a 50% score reduction on a depression scale after completion of treatment. Secondary outcomes (also measured as dichotomous) were early remission (defined as having a symptom score below a fixed threshold after completion of treatment), lost to follow-up, lost to follow-up due to adverse events, and any adverse event. The odds ratio was used as effect measure.

This data set was used as an example in Rucker and Schwarzer (2017) who introduced methods to resolve conflicting rankings of outcomes in network meta-analysis.

## Concepts

medicine, psychiatry, odds ratios, network meta-analysis

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Linde, K., Kriston, L., Rucker, G., Jamil, S., Schumann, I., Meissner, K., Sigterman, K., & Schneider, A. (2015). Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. *Annals of Family Medicine*, **13**(1), 69–79. doi:10.1370/afm.1687

## References

Rücker, G., & Schwarzer, G. (2017). Resolve conflicting rankings of outcomes in network meta-analysis: Partial ordering of treatments. *Research Synthesis Methods*, **8**(4), 526–536. doi:10.1002/jrsm.1270

## Examples

```

if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Change appearance of confidence intervals
cilayout("(", "-")

# Define order of treatments in printouts
trts <- c("TCA", "SSRI", "SNRI", "NRI", "Low-dose SARI",
"NaSSa", "rMAO-A", "Hypericum", "Placebo")

# Transform data from wide arm-based format to contrast-based format
# (outcome: early response). Argument 'sm' has to be used for odds
# ratio as summary measure; by default the risk ratio is used in the
# metabin function called internally.
pw1 <- pairwise(list(treatment1, treatment2, treatment3),
  event = list(resp1, resp2, resp3),
  n = list(n1, n2, n3),
  studlab = id, data = Linde2015, sm = "OR")

# Conduct random effects network meta-analysis for primary outcome
# (early response); small number of early responses is bad (argument
# small.values)
nma1 <- netmeta(pw1, common = FALSE, reference = "Placebo", seq = trts,
  small.values = "undesirable")
nma1

# Random effects NMA for early remission
pw2 <- pairwise(treat = list(treatment1, treatment2, treatment3),
  event = list(remi1, remi2, remi3),
  n = list(n1, n2, n3),
  studlab = id, data = Linde2015, sm = "OR")
nma2 <- netmeta(pw2, common = FALSE,
  seq = trts, ref = "Placebo", small.values = "undesirable")
nma2

# Ranking of treatments
nr1 <- netrank(nma1)
nr2 <- netrank(nma2)
nr1
nr2

```

```

# Partial order of treatment rankings (two outcomes)
outcomes <- c("Early response", "Early remission")
po12 <- netposet(nr1, nr2, outcomes = outcomes)
plot(po12)

# Use previous settings
settings.meta(oldset)
}

```

---

Linde2016

---

*Studies on Antidepressants for the Primary Care Setting*


---

### Description

Results from 93 trials examining 22 interventions (including placebo and usual care) for the primary care of depression.

### Usage

```
Linde2016
```

### Format

The data frame contains the following columns:

<b>id</b>	integer	study ID
<b>author</b>	character	first author
<b>year</b>	numeric	year of publication
<b>resp</b>	numeric	number of responders
<b>n</b>	numeric	number of patients
<b>int</b>	character	intervention label
<b>int.long</b>	character	intervention label (full name)

### Details

This data set comes from a network meta-analysis of 22 treatments of depression in primary care (Linde et al., 2016), based on 93 trials (79 two-arm trials, 13 three-arm trials, and one four-arm trial). The primary outcome was response after treatment (yes/no), defined as a reduction from baseline by at least 50% on a depression scale. This data set contains log odds ratios with standard errors for all pairwise comparisons.

The interventions comprised both medical and psychological treatments, also in combination, including placebo and usual care (UC) (Linde et al., 2016). Pharmacological interventions were tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin-noradrenaline reuptake inhibitors (SNRI), noradrenaline reuptake inhibitors (NRI), low-dose serotonin (5-HT<sub>2</sub>) antagonists and reuptake inhibitors (low-dose SARI), noradrenergic and specific serotonergic agents

(NaSSa), reversible inhibitors of monoaminoxidase A (rMAO-A), hypericum extracts, and an individualized drug. Psychological interventions were cognitive behavioral therapy (CBT; four forms: face-to-face CBT, remote therapist-led CBT, guided self-help CBT, and no or minimal contact CBT), face-to-face problem-solving therapy (PST), face-to-face interpersonal psychotherapy, face-to-face psychodynamic therapy, and “other face-to-face therapy”. Combination therapies were face-to-face CBT + SSRI, face-to-face PST + SSRI, and face-to-face interpersonal psychotherapy + SSRI.

This data set was used as an example in Rucker et al. (2020) to illustrate component network meta-analysis using frequentist methods.

### Concepts

medicine, psychiatry, odds ratios, network meta-analysis, component network meta-analysis

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

### Source

Linde, K., Rucker, G., Schneider, A., & Kriston, L. (2016). Questionable assumptions hampered interpretation of a network meta-analysis of primary care depression treatments. *Journal of Clinical Epidemiology*, **71**, 86–96. doi:10.1016/j.jclinepi.2015.10.010

### References

Rucker, G., Petropoulou, M., & Schwarzer, G. (2020). Network meta-analysis of multicomponent interventions. *Biometrical Journal*, **62**(3), 808–821. doi:10.1002/bimj.201800167

### Examples

```
if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

# Define order of treatments in printouts and forest plots
trts <- c("SSRI",
  "Face-to-face CBT", "Face-to-face interpsy", "Face-to-face PST",
  "Face-to-face CBT + SSRI", "Face-to-face interpsy + SSRI",
  "Face-to-face PST + SSRI",
  "Face-to-face psychodyn", "Other face-to-face",
  "TCA", "SNRI", "NRI", "Low-dose SARI", "NaSSa", "rMAO-A", "Ind drug",
  "Hypericum",
  "Remote CBT", "Self-help CBT", "No contact CBT",
  "UC", "Placebo")

# Use pairwise() to transform data to comparison-based format
pw <- pairwise(treat = int,
```

```

event = resp, n = n,
studlab = paste(author, year),
data = Linde2016,
reference = "plac",
sm = "OR")

# Conduct random effects network meta-analysis
nma <- netmeta(pw, reference.group = "placebo",
  seq = trts, common = FALSE)

# Network graph
netgraph(nma, seq = "o")

# Show results
nma
forest(nma, xlim = c(0.2, 50))

# Additive component network meta-analysis with placebo as inactive
# treatment
cnma <- netcomb(nma, inactive = "placebo")
cnma
forest(cnma, xlim = c(0.2, 50))

# Use previous settings
settings.meta(oldset)
}

```

---

Lloyd2010

---

*Studies on Anti-TNF-alpha Inhibitors in Rheumatoid Arthritis*


---

## Description

Results from 16 studies evaluating anti-TNF-alpha inhibitors in patients with rheumatoid arthritis.

## Usage

Lloyd2010

## Format

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>mean.das</b>	numeric	mean for outcome DAS-28
<b>lower.das</b>	numeric	lower limit for outcome DAS-28
<b>upper.das</b>	numeric	upper limit for outcome DAS-28
<b>mean.haq</b>	numeric	mean for outcome HAQ

<b>lower.haq</b>	numeric	lower limit for outcome HAQ
<b>upper.haq</b>	numeric	upper limit for outcome HAQ
<b>n</b>	integer	sample size

## Details

Lloyd et al. (2010) report results of a systematic review evaluating the effectiveness of anti-TNF-alpha inhibitors in the treatment of rheumatoid arthritis. The authors conducted separate meta-analyses for HAQ and DAS-28.

## Concepts

medicine, mean differences

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Lloyd, S., Bujkiewicz, S., Wailoo, A.J., et al. (2010). The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis. *Rheumatology (Oxford)*, **49**, 2313-21. doi:[10.1093/rheumatology/keq169](https://doi.org/10.1093/rheumatology/keq169)

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Only consider studies providing data for both outcomes
lloyd5 <- subset(Lloyd2010, !is.na(mean.haq) & !is.na(mean.das))

# Univariate meta-analysis of the DAS-28 outcome
m.das <- metagen(mean.das,
  lower = lower.das, upper = upper.das,
  data = lloyd5, sm = "MD",
  studlab = paste(author, year),
  random = FALSE)
# Univariate meta-analysis of the HAQ outcome
m.haq <- metagen(mean.haq,
  lower = lower.haq, upper = upper.haq,
  data = lloyd5, sm = "MD",
  studlab = paste(author, year),
  random = FALSE)

# Forest plots
forest(m.das, test.overall = TRUE, hetstat = FALSE,
  digits.TE = 2, digits.se = 2)
forest(m.haq, test.overall = TRUE, hetstat = FALSE,
```

```

    digits.TE = 2, digits.se = 2)
}

```

Moore1998

*Trials on Non-Steroidal Anti-Inflammatory Drugs in Acute Pain***Description**

Results from 37 trials evaluating non-steroidal anti-inflammatory drugs (NSAIDS) in patients with acute pain.

**Usage**

Moore1998

**Format**

The data frame contains the following columns:

<b>id</b>	integer	study ID
<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>Ee</b>	integer	number of treatment successes (NSAIDS group)
<b>Ne</b>	integer	number of patients (NSAIDS group)
<b>Ec</b>	integer	number of treatment successes (control group)
<b>Nc</b>	integer	number of patients (control group)
<b>nonenglish</b>	integer	non-English publication
<b>medline</b>	integer	listed in Medline
<b>grey</b>	integer	grey literature
<b>samecont</b>	integer	same control group
<b>journal</b>	character	journal

**Details**

Moore et al. (1998) conducted a systematic review of 37 randomised placebo-controlled trials on the effectiveness and safety of topical non-steroidal anti-inflammatory drugs (NSAIDS) in acute pain. The main outcome was treatment success, defined as a reduction in pain of at least 50%.

This data set is used as an example in Schwarzer et al. (2015).

**Concepts**

medicine, odds ratios, publication bias

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Moore, R. A., Tramèr, M. R., Carroll, D., et al. (1998). Quantitative systematic Review of topically applied non-steroidal anti-inflammatory drugs. *British Medical Journal*, **316**, 333-38

**References**

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Conduct meta-analysis
m <- metabin(Ee, Ne, Ec, Nc, data = Moore1998,
  sm = "OR", studlab = id,
  label.e = "NSAIDS", label.c = "Placebo")

# Funnel plot
fun <- funnel(m, type = "contour",
  random = FALSE, pch = 16)
legend(0.25, 1.25, bty = "n",
  legend = fun$text.contour, fill = fun$col.contour)
}
```

---

Poole2003

*Trials on Mucolytic Agents in Chronic Bronchitis or Chronic Obstructive Pulmonary Disease*

---

**Description**

Results from 19 trials evaluating mucolytic agents in patients with chronic bronchitis or chronic obstructive pulmonary disease.

**Usage**

Poole2003

**Format**

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>Ne</b>	integer	sample size (mucolytic agents)

<b>Me</b>	numeric	mean exacerbations per months (mucolytic agents)
<b>Se</b>	numeric	standard deviation (mucolytic agents)
<b>Nc</b>	integer	sample size (placebo)
<b>Mc</b>	numeric	mean exacerbations per months (placebo)
<b>Sc</b>	numeric	standard deviation (placebo)
<b>duration</b>	character	study duration

## Details

Poole and Black (2003) conducted a Cochrane review to evaluate mucolytic agents versus placebo for patients with chronic bronchitis or chronic obstructive pulmonary disease. The outcome used here is the mean number of acute exacerbations per month. Acute exacerbation is defined as an increase in cough and in the volume or purulence of sputum. All 17 studies included in the meta-analysis report a mean number of exacerbations and we can work with mean differences, rather than standardised mean differences. Note, later versions of this Cochrane review no longer evaluate the mean number of exacerbations per month.

This data set is used as an example in Schwarzer et al. (2015).

## Concepts

medicine, mean differences, subgroup analysis

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Poole, P.J., Black, P.N. (2003). Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, **1**, doi:[10.1002/14651858.CD001287](https://doi.org/10.1002/14651858.CD001287)

## References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
  # Load meta package
  library("meta")

  # Use RevMan 5 settings
  oldset <- settings.meta("RevMan5",
    digits.I2 = 2, digits.tau = 3, digits.sd = 2)

  # Conduct random effects meta-analysis
  m <- metacont(Ne, Me, Se, Nc, Mc, Sc, data = Poole2003,
    studlab = paste(author, year), common = FALSE,
```

```

subgroup = duration,
subgroup.name = "Duration", sep.subgroup = ": ",
label.e = "Mucolytic agent",
label.c = "Placebo",
label.left = "Favours mucolytic agent",
label.right = "Favours placebo",
col.label.left = "green", col.label.right = "red")

# Forest plot
forest(m, xlim = c(-0.5, 0.2),
  xlab = paste0("Difference in mean number of\n",
    "acute exacerbations per month"))

# Use previous settings
settings.meta(oldset)
}

```

---

Quan2000

*Studies on Pharmacotherapy for Hypertension*


---

## Description

Results from 11 studies evaluating pharmacotherapy in patients with hypertension.

## Usage

Quan2000

## Format

The data frame contains the following columns:

<b>study</b>	character	study label
<b>Ee</b>	integer	fatal cerebrovascular events (pharmacotherapy)
<b>Ne</b>	integer	number of patients (pharmacotherapy)
<b>Ec</b>	integer	fatal cerebrovascular events (control)
<b>Nc</b>	integer	number of patients (control)

## Details

Quan et al. (2000) conducted a Cochrane Review to evaluate whether the benefit of treating hypertension in women differed between younger and older women, as well as between white and African American women. In the systematic review, the Peto method was used for pooling. The primary outcome was the occurrence of fatal cerebrovascular events, a rare event in hypertension. This data set contains the subgroup of women older than 55 years.

This data set is used as an example in Schwarzer et al. (2015).

**Concepts**

medicine, Peto's method

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Quan, A.P., Kerlikowske, K. Gueyffier, F., et al., & Indana Investigators (2000). Pharmacotherapy for hypertension in women of different races. *Cochrane Database of Systematic Reviews*, **2**, doi:[10.1002/14651858.CD002146](https://doi.org/10.1002/14651858.CD002146)

**References**

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {  
  # Load meta package  
  library("meta")  
  
  # Use RevMan 5 settings  
  oldset <- settings.meta("RevMan5")  
  
  # Conduct meta-analysis with Peto method  
  m <- metabin(Ee, Ne, Ec, Nc, sm = "OR", method = "Peto",  
    data = Quan2000, studlab = study, random = FALSE)  
  m  
  
  # Use previous settings  
  settings.meta(oldset)  
}
```

---

Senn2013

*Studies on Diabetes Treatments*

---

**Description**

Results from 26 trials evaluating treatments for diabetes.

**Usage**

Senn2013

## Format

The data frame contains the following columns:

<b>study</b>	character	study ID
<b>treatment</b>	character	treatment
<b>n</b>	integer	sample size
<b>mean</b>	numeric	mean
<b>sd</b>	numeric	standard deviation
<b>type</b>	character	outcome type
<b>author</b>	character	first author
<b>year</b>	numeric	first author

## Details

This network meta-analysis compared the effectiveness of nine active treatments and placebo in patients with diabetes (Senn et al., 2013). Patients enrolled in 26 studies included in this data set were treated to reduce blood glucose (HbA1c) levels. The effect measure was the mean difference of average plasma glucose concentration HbA1c and measured in mmol / mol. The outcome was either measured as a change score or post intervention (variable type).

## Concepts

medicine, diabetes, mean differences, network meta-analysis

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Senn S, Gavini F, Magrez D, Scheen A (2013): Issues in performing a network meta-analysis. *Statistical Methods in Medical Research*, **22**, 169–89

## Examples

```
if (requireNamespace("netmeta", quietly = TRUE)) {
  # Load netmeta package
  library("netmeta")

  # Print mean differences with two digits
  oldset <- settings.meta(digits = 2)

  # Transform data from long arm-based format to contrast-based
  # format.
  pw1 <- pairwise(studlab = study, treat = treatment,
    n = n, mean = mean, sd = sd, data = Senn2013,
    varnames = c("MD", "seMD"))

  # Conduct network meta-analysis
```

```

nma1 <- netmeta(pw1, random = FALSE,
  reference.group = "placebo")
nma1

# Draw network graph
netgraph(nma1, seq = "optimal", multiarm = TRUE,
  cex = 1.5, lwd = 7, rotate = -1 / n * 360,
  pch.points = 21, bg.points = "lightblue",
  cex.points = n.trts, points.max = 10,
  labels = paste0(trts, "\n(n=", n.trts, ")"),
  offset = 0.045)

# Use previous settings
settings.meta(oldset)
}

```

---

Senn2024

*Data of n-of-1 Meta-Analysis in Asthma*


---

## Description

Results from 12 simulated patients in n-of-1 meta-analysis in asthma (Senn, 2024).

## Usage

Senn2024

## Format

The data frame contains the following columns:

<b>patid</b>	integer	patient ID
<b>n.cycles</b>	numeric	number of cycles
<b>md</b>	numeric	mean difference
<b>var.md</b>	integer	variance of mean difference

## Details

Senn (2024) simulated data from 12 patients to describe a meta-analysis method of n-of-1 trials.

## Concepts

medicine, asthma, mean differences, n-of-1 meta-analysis

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Senn S (2024): The analysis of continuous data from n-of-1 trials using paired cycles: a simple tutorial. *Trials*, **25**, 128

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
  # Load meta package
  library("meta")

  mg4 <- metagen(md, sqrt(var.md), cycles = n.cycles,
    data = Senn2024, studlab = paste("Patient", patid),
    sm = "MD", method.tau = "DL")
  #
  forest(mg4, digits.TE = 2, digits.se = 2,
    digits.sd = 2, digits.tau2 = 1, digits.weight = 2,
    xlim = c(-200, 550), at = c(-200, 0, 200, 400),
    details = TRUE)
}
```

---

Spooner2002

*Studies on Nedocromil Sodium for Preventing Exercise-Induced Bronchoconstriction*

---

## Description

Results from 17 trials, 11 studies in children and 6 studies in adults, reporting the maximum fall in the forced expiratory volume in 1 second (FEV<sub>1</sub>) over the course of follow-up, expressed as a percentage.

## Usage

Spooner2002

## Format

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	character	year of publication
<b>Ne</b>	integer	number of participants in nedocromil sodium group
<b>Me</b>	numeric	maximum fall in the FEV <sub>1</sub> (nedocromil sodium)
<b>Se</b>	numeric	standard deviation (nedocromil sodium)
<b>Nc</b>	integer	number of participants in placebo group
<b>Mc</b>	numeric	maximum fall in the FEV <sub>1</sub> (placebo)
<b>Sc</b>	numeric	standard deviation (placebo)
<b>agegroup</b>	factor	age group (children or adults)

## Details

Spooner et al. (2002) conducted a Cochrane review comparing nedocromil sodium (experimental treatment) with placebo (control) for preventing exercise-induced bronchoconstriction. Primary outcome was the maximum fall in the forced expiratory volume in 1 second (FEV<sub>1</sub>) over the course of follow-up, expressed as a percentage. This outcome is available for 17 studies, 11 studies in children and 6 studies in adults. For each study, the mean value, standard deviation, and sample size are reported for both the experimental and control group. The authors conducted a random-effects meta-analysis with the mean difference as effect measure, i.e. mean value in the nedocromil sodium group minus mean value in the placebo group.

This data set is used as an example in Schwarzer et al. (2015).

## Concepts

mean differences, subgroup analysis

## Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

## Source

Spooner, C., Saunders, L. D., & Rowe, B. H. (2002). Nedocromil sodium for preventing exercise-induced bronchoconstriction. *Cochrane Database of Systematic Reviews*, **1**, CD001183. doi:10.1002/14651858.CD001183

## References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

## Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Use settings from RevMan5
oldset <- settings.meta("RevMan5")

# Conduct random effects meta-analysis with age subgroups
mc1 <- metacont(Ne, Me, Se, Nc, Mc, Sc,
               data = Spooner2002, studlab = paste(author, year),
               subgroup = agegroup, print.subgroup.name = FALSE,
               label.e = "Nedocromil sodium", label.c = "Placebo",
               common = FALSE)

mc1

# Use previous settings
```

```
settings.meta(oldset)
}
```

---

Steurer2006	<i>Trials on Single-Agent Purine Analogues for the Treatment of Chronic Lymphocytic Leukaemia</i>
-------------	---

---

### Description

Results from 4 trials evaluating single-agent purine analogues in patients with chronic lymphocytic leukaemia.

### Usage

Steurer2006

### Format

The data frame contains the following columns:

<b>author</b>	character	first author
<b>year</b>	integer	publication year
<b>Ne</b>	integer	number of patients (purine antagonists)
<b>Nc</b>	integer	number of patients (alkylator-based)
<b>HR</b>	numeric	hazard ratio
<b>lowHR</b>	numeric	lower limit
<b>uppHR</b>	numeric	upper limit
<b>lnHR</b>	numeric	log hazard ratio
<b>selnHR</b>	numeric	standard error

### Details

Steurer et al. (2006) conducted a Cochrane review to evaluate the effect of single-agent purine analogues for the treatment of chronic lymphocytic leukaemia. This data set contains data from the main outcome, overall survival. Note, the hazard ratios and confidence limits have been reported in the Cochrane review with only two significant figures and were recalculated using the reported log hazard ratios and standard errors.

This data set is used as an example in Schwarzer et al. (2015).

### Concepts

medicine, oncology, hazard ratios

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Steurer, M., Pall, G., Richards, S., et al. (2006). Purine antagonists for chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews*, **3**, doi:10.1002/14651858.CD004270.pub2

**References**

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

**Examples**

```
if (requireNamespace("meta", quietly = TRUE)) {
  # Load meta package
  library("meta")

  # Use RevMan 5 settings
  oldset <- settings.meta("RevMan5")

  # Conduct common effect meta-analysis
  m1 <- metagen(lnHR, selnHR, data = Steurer2006,
    studlab = paste(author, year),
    sm = "HR", random = FALSE, n.e = Ne, n.c = Nc)
  m1

  # Same analysis using lower and upper confidence limits
  m2 <- metagen(HR, lower = lowHR, upper = uppHR,
    data = Steurer2006, transf = FALSE,
    studlab = paste(author, year),
    sm = "HR", random = FALSE, n.e = Ne, n.c = Nc)
  m2

  # Use previous settings
  settings.meta(oldset)
}
```

---

Stowe2010

*Studies on Adjuvant Treatments to Levodopa Therapy for Parkinson disease*

---

**Description**

Results from 29 trials assessing efficacy of three drug classes as adjuvant treatment to levodopa therapy in patients with Parkinson disease and motor complications.

**Usage**

Stowe2010

**Format**

The data frame contains the following columns:

<b>study</b>	character	study label
<b>id</b>	integer	study id
<b>t1</b>	character	treatment 1
<b>y1</b>	numeric	treatment effect arm 1
<b>sd1</b>	numeric	standard deviation arm 1
<b>n1</b>	integer	sample size arm 1
<b>t2</b>	character	treatment 2
<b>y2</b>	numeric	treatment effect arm 2
<b>sd2</b>	numeric	standard deviation arm 2
<b>n2</b>	integer	sample size arm 2
<b>t3</b>	character	treatment 3
<b>y3</b>	numeric	treatment effect arm 3
<b>sd3</b>	numeric	standard deviation arm 3
<b>n3</b>	integer	sample size arm 3

**Details**

This data set contains data from a Cochrane review assessing efficacy and safety of three drug classes as adjuvant treatment to levodopa therapy in patients with Parkinson disease and motor complications (Stowe et al., 2010).

The authors conducted three pairwise meta-analyses comparing dopamine agonists, catechol-O-methyl transferase inhibitors (COMTI), and monoamine oxidase type B inhibitors (MAOBI) with placebo. The primary outcome was the mean reduction of the time spent in a relatively immobile 'off' phase (mean off-time), calculated in hours per day. Relative treatment effects were expressed as mean difference. Data on this outcome were available for 5,331 patients from 28 studies comparing an active treatment with placebo and one three-arm study comparing two active treatments with placebo.

**Concepts**

medicine, mean differences, network meta-analysis

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Stowe, R., Ives, N., Clarke, C. E., Deane, K., Hilten, V., Wheatley, K., Gray, R., Handley, K., & Furmston, A. (2010). Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. *Cochrane Database of Systematic Reviews*, 7, CD007166. doi:10.1002/14651858.CD007166.pub2

**Examples**

```
if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Print mean differences with two digits and standard errors with 3
# digits
oldset <- settings.meta(digits = 2, digits.se = 3)

# Transform data from wide arm-based format to contrast-based
# format. Argument 'sm' must not be provided as the mean difference
# is the default in R function metacont() called internally.
pw <- pairwise(treat = list(t1, t2, t3), n = list(n1, n2, n3),
  mean = list(y1, y2, y3), sd = list(sd1, sd2, sd3),
  studlab = study, data = Stowe2010, sm = "MD")

# Show calculated mean differences (TE) for three studies
selstudy <- c("COMTI(E) INT-OZ", "LARGO", "COMTI(E) Nomecomt")
subset(pw, studlab %in% selstudy)[, c(3:7, 10, 1)]

# Conduct random effects network meta-analysis (NMA)
# with placebo as reference
nma <- netmeta(pw, common = FALSE, ref = "plac")

# Show network graph
netgraph(nma, number = TRUE, multiarm = TRUE,
  cex = 1.25, offset = 0.025,
  cex.number = 1, pos.number.of.studies = 0.3)

# Print NMA results
nma

# Forest plot with NMA results
forest(nma)

# Forest plot showing all network estimates of active treatments
# compared with other treatments
forest(nma, ref = c("C", "D", "M"), baseline = FALSE, drop = TRUE)

# Treatment ranking using P-scores
netrank(nma)

# Rankogram with all ranking probabilities
set.seed(1909)
ran <- rankogram(nma)
ran
plot(ran)

# Treatment ranking using SUCRAs
netrank(ran)

# League table showing network and direct estimates
```

```
netleague(nma, seq = netrank(nma), ci = FALSE)

# Use previous settings
settings.meta(oldset)
}
```

---

Su2018	<i>Studies on Interventions for Patients with Periodontal Infrabony Lesions</i>
--------	---

---

### Description

Results from 52 trials comparing guided tissue regeneration, enamel matrix derivatives, and their combination therapies or patients with periodontal infrabony lesions.

### Usage

Su2018

### Format

The data frame contains the following columns:

<b>id</b>	numeric	study ID
<b>study</b>	character	study label
<b>trt</b>	character	treatment
<b>n</b>	numeric	number of individuals
<b>change</b>	numeric	change in clinical attachment level
<b>sd</b>	numeric	standard deviation
<b>author</b>	character	first author
<b>year</b>	numeric	year of publication

### Details

This data set comes from a systematic review of randomized controlled trials on eight interventions for patients with periodontal infrabony lesions (Su and Tu, 2018). The continuous outcome was change in clinical attachment between baseline and 12 months after treatment. The studies either used a parallel or split-mouth design.

### Concepts

dentistry, correlated, mean differences, network meta-analysis

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Su Y, Tu Y (2018): Statistical approaches to adjusting weights for dependent arms in network meta-analysis. *Research Synthesis Methods*, **9**, 431–40. doi:10.1002/jrsm.1304

**Examples**

```
if (requireNamespace("netmeta", quietly = TRUE)) {
# Load netmeta package
library("netmeta")

# Transform data from long arm-based format to contrast-based format
pw <- pairwise(trt, n = n, mean = change, sd = sd,
  data = Su2018, studlab = study)

# Conduct random effects network meta-analysis (NMA) with
# - flap operation as reference
# - results from split-mouth designs as correlated outcomes
nma <- netmeta(pw, common = FALSE, reference = "Flap op",
  correlated = design == "split")

# Show network graph
netgraph(nma, seq = "o")

# Print results for network meta-analysis
nma
}
```

---

Thompson1999

---

*Trials on Serum Cholesterin Concentration Lowering and Risk of Ischaemic Heart Disease*


---

**Description**

Results from 28 trials evaluating effect of serum cholesterin concentration lowering on risk of ischaemic heart disease

**Usage**

Thompson1999

**Format**

The data frame contains the following columns:

<b>studyid</b>	integer	study ID
<b>ihd.cont</b>	integer	number of ischaemic heart disease (control group)
<b>noihd.cont</b>	integer	number of non-events (control group)

<b>ihd.exp</b>	integer	number of ischaemic heart disease (treated group)
<b>noihd.exp</b>	integer	number of non-events (treated group)
<b>OR</b>	numeric	odds ratio
<b>logOR</b>	numeric	log odds ratio
<b>varlogOR</b>	numeric	variance of log odds ratio
<b>cholr</b>	numeric	cholesterol reduction (mmol/l)

### Details

Thompson & Sharp (1999) compare several meta-regression approaches to explain heterogeneity in meta-analysis. The data set used goes back to Law et al. (1994).

### Concepts

epidemiology, odds ratios, meta-regression

### Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

### Source

Thompson, S. G. Sharp, S. J. (1999). Explaining heterogeneity in meta-analysis: a comparison of methods. *Statistics in Medicine*, **18**: 2693-708

### References

Law, M.R., Wald, N.J., Thompson, S.G. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *British Medical Journal*, **308**, 367-73

### Examples

```
if (requireNamespace("meta", quietly = TRUE)) {
# Load meta package
library("meta")

# Conduct meta-analysis
ma <- metabin(ihd.exp, ihd.exp + noihd.exp, ihd.cont, ihd.cont + noihd.cont,
  data = Thompson1999, sm = "OR", method = "Inverse")

# Thompson & Sharp (1999), Table III
# (1) None
metareg(ma, cholr, method.tau = "FE")
# (3a) Additive (MM)
metareg(ma, cholr, method.tau = "DL")
}
```

Woods2010

*Studies on Treatments for Chronic Obstructive Pulmonary Disease***Description**

Results from three trials examining the mortality risk of three treatments and placebo in patients with chronic obstructive pulmonary disease.

**Usage**

Woods2010

**Format**

The data frame contains the following columns:

<b>author</b>	character	first author / study name
<b>treatment</b>	character	treatment
<b>r</b>	integer	number of deaths
<b>N</b>	integer	number of patients

**Details**

Count mortality statistics in randomised controlled trials of treatments for chronic obstructive pulmonary disease (Woods et al., 2010, Table 1).

**Concepts**

medicine, odds ratios, network meta-analysis

**Author(s)**

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>

**Source**

Woods BS, Hawkins N, Scott DA (2010): Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial. *BMC Medical Research Methodology*, **10**, 54. doi:[10.1186/147122881054](https://doi.org/10.1186/147122881054)

**Examples**

```
if (requireNamespace("netmeta", quietly = TRUE)) {
  # Load netmeta package
  library("netmeta")

  # Print odds ratios and confidence limits with two digits
  oldset <- settings.meta(digits = 2)
```

```
# Change appearance of confidence intervals
cilayout("(", "-")

# Transform data from long arm-based format to contrast-based
# format. Argument 'sm' has to be used for odds ratio as summary
# measure; by default the risk ratio is used in the metabin function
# called internally.
pw <- pairwise(treatment, event = r, n = N,
  studlab = author, data = Woods2010, sm = "OR")
pw

# Conduct network meta-analysis
nma <- netmeta(pw)
nma

# Show forest plot
forest(nma, ref = "Placebo", drop = TRUE,
  leftlabs = "Contrast to Placebo")

# Use previous settings
settings.meta(oldset)
}
```

# Index

- \* **Mantel-Haenszel method**
  - Dogliotti2014, [8](#)
  - Dong2013, [10](#)
  - Gurusamy2011, [19](#)
- \* **Peto's method**
  - Quan2000, [38](#)
- \* **asthma**
  - Senn2024, [41](#)
- \* **component network meta-analysis**
  - Baker2009, [3](#)
  - Hamza2021, [22](#)
  - Linde2016, [31](#)
- \* **correlated**
  - Su2018, [48](#)
- \* **data sets**
  - Baker2009, [3](#)
  - Bassler2004, [4](#)
  - Curtin2002, [6](#)
  - Dogliotti2014, [8](#)
  - Dong2013, [10](#)
  - Feng2019, [11](#)
  - Franchini2012, [13](#)
  - Furukawa2003, [15](#)
  - Greb2008, [16](#)
  - Greenland1992, [18](#)
  - Gurusamy2011, [19](#)
  - Hamza2021, [22](#)
  - Higgins2008, [23](#)
  - Hong2015, [25](#)
  - Jalota2011, [27](#)
  - Linde2015, [28](#)
  - Linde2016, [31](#)
  - Lloyd2010, [33](#)
  - Moore1998, [35](#)
  - Poole2003, [36](#)
  - Quan2000, [38](#)
  - Senn2013, [39](#)
  - Senn2024, [41](#)
  - Spooner2002, [42](#)
  - Steurer2006, [44](#)
  - Stowe2010, [45](#)
  - Su2018, [48](#)
  - Thompson1999, [49](#)
  - Woods2010, [51](#)
- \* **dentistry**
  - Su2018, [48](#)
- \* **depression**
  - Hamza2021, [22](#)
- \* **diabetes**
  - Senn2013, [39](#)
- \* **epidemiology**
  - Greenland1992, [18](#)
  - Thompson1999, [49](#)
- \* **hazard ratios**
  - Steurer2006, [44](#)
- \* **mean differences**
  - Curtin2002, [6](#)
  - Franchini2012, [13](#)
  - Hong2015, [25](#)
  - Lloyd2010, [33](#)
  - Poole2003, [36](#)
  - Senn2013, [39](#)
  - Senn2024, [41](#)
  - Spooner2002, [42](#)
  - Stowe2010, [45](#)
  - Su2018, [48](#)
- \* **medicine**
  - Baker2009, [3](#)
  - Bassler2004, [4](#)
  - Dogliotti2014, [8](#)
  - Dong2013, [10](#)
  - Franchini2012, [13](#)
  - Greb2008, [16](#)
  - Gurusamy2011, [19](#)
  - Hamza2021, [22](#)
  - Hong2015, [25](#)
  - Jalota2011, [27](#)
  - Linde2015, [28](#)

- Linde2016, [31](#)
- Lloyd2010, [33](#)
- Moore1998, [35](#)
- Poole2003, [36](#)
- Quan2000, [38](#)
- Senn2013, [39](#)
- Senn2024, [41](#)
- Steurer2006, [44](#)
- Stowe2010, [45](#)
- Woods2010, [51](#)
- \* **meta-regression**
  - Thompson1999, [49](#)
- \* **missing data**
  - Higgins2008, [23](#)
- \* **n-of-1 meta-analysis**
  - Senn2024, [41](#)
- \* **network meta-analysis**
  - Baker2009, [3](#)
  - Dogliotti2014, [8](#)
  - Dong2013, [10](#)
  - Franchini2012, [13](#)
  - Gurusamy2011, [19](#)
  - Hong2015, [25](#)
  - Jalota2011, [27](#)
  - Linde2015, [28](#)
  - Linde2016, [31](#)
  - Senn2013, [39](#)
  - Stowe2010, [45](#)
  - Su2018, [48](#)
  - Woods2010, [51](#)
- \* **odds ratios**
  - Baker2009, [3](#)
  - Dogliotti2014, [8](#)
  - Dong2013, [10](#)
  - Gurusamy2011, [19](#)
  - Hamza2021, [22](#)
  - Higgins2008, [23](#)
  - Linde2015, [28](#)
  - Linde2016, [31](#)
  - Moore1998, [35](#)
  - Thompson1999, [49](#)
  - Woods2010, [51](#)
- \* **oncology**
  - Greb2008, [16](#)
  - Steurer2006, [44](#)
- \* **package**
  - metabook-package, [2](#)
- \* **pain**
  - Hong2015, [25](#)
  - Jalota2011, [27](#)
- \* **prevalence**
  - Feng2019, [11](#)
- \* **psychiatry**
  - Higgins2008, [23](#)
  - Linde2015, [28](#)
  - Linde2016, [31](#)
- \* **publication bias**
  - Moore1998, [35](#)
- \* **pulmonology**
  - Baker2009, [3](#)
- \* **risk ratios**
  - Bassler2004, [4](#)
  - Greb2008, [16](#)
  - Greenland1992, [18](#)
  - Jalota2011, [27](#)
- \* **standardized mean differences**
  - Furukawa2003, [15](#)
- \* **subgroup analysis**
  - Bassler2004, [4](#)
  - Poole2003, [36](#)
  - Spooner2002, [42](#)
- Baker2009, [3](#)
- Bassler2004, [4](#)
- Curtin2002, [6](#)
- Dogliotti2014, [8](#)
- Dong2013, [9](#)
- Feng2019, [11](#)
- Franchini2012, [13](#)
- Furukawa2003, [15](#)
- Greb2008, [16](#)
- Greenland1992, [18](#)
- Gurusamy2011, [19](#)
- Hamza2021, [22](#)
- Higgins2008, [23](#)
- Hong2015, [25](#)
- Jalota2011, [27](#)
- Linde2015, [28](#)
- Linde2016, [31](#)
- Lloyd2010, [33](#)
- metabook (metabook-package), [2](#)

metabook-package, [2](#)  
Moore1998, [35](#)

Pooler2003, [36](#)

Quan2000, [38](#)

Senn2013, [39](#)

Senn2024, [41](#)

Spooner2002, [42](#)

Steurer2006, [44](#)

Stowe2010, [45](#)

Su2018, [48](#)

Thompson1999, [49](#)

Woods2010, [51](#)